“…Antibodies against classic biomarkers have been studied, and are still being analyzed in terms of biodistribution, their ability to penetrate tissue, toxicity, and efficient clearance. Some examples include scFvs directed against chondroitin sulfate (CS, abundant in the extracellular matrix in ovarian cancer) [ 94 ], CD24 (overexpressed in several tumors and in cancerous stem cells) [ 95 ], oncoprotein E6, expressed continuously in carcinomas associated with human papilloma virus type 16 (HPV 16) [ 96 ], gastrin receptor (CCK2R, playing a key role in the trigger and development of cancer) [ 97 ], dehydroepiandrosterone (DHEA, adrenocortical carcinoma marker) [ 98 ], against cancer cells overexpressing EGFR (epidermal growth factor receptor) [ 99 ], MCF-7 breast cancer cells [ 100 , 101 ], and SUM159 (breast cancer stem cells) [ 102 ]. They have all shown promising results.…”